This study evaluates the effect of a 'lithium like' drug called ebselen (SP-1005) versus
placebo as an 'add on' treatment to help stabilise hypo/manic symptoms in bipolar disorder.
Half of the participants will receive ebselen and the other half placebo. The trial, will
last a total of four weeks.
Phase:
Phase 2
Details
Lead Sponsor:
University of Oxford
Collaborators:
Sound Pharmaceuticals, Incorporated Stanley Medical Research Institute